Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Consolidation for High-risk CLL Patients on Ibrutinib or Acalabrutinib
NCT03128879Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Minimal Residual Disease Negativity Rate at 1 year. Started Jun 2017; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03128879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128879.